Molecular mechanisms of resistance in testicular germ cell tumors - Clinical implications

Testicular germ cell tumors (TGCTs) represent the most common malignancy in men aged 15-35. Due to these tumors' biological and clinical characteristics, they can serve as an appropriate system for studying molecular mechanisms associated with cisplatin-based treatment resistance. This review describes treatment resistance from clinical and molecular viewpoints. Cisplatin resistance is determined by various biological mechanisms, including the modulation of the DNA repair capacity of cancer cells, alterations to apoptotic cell death pathways, deregulation of gene expression pathways, epigenetic alterations and insufficient DNA binding. Moreover, this review describes TGCTs as a model system that enables the study of the cellular features of cancer stem cells in metastatic process and describes experimental models that can be used to study treatment resistance in TGCTs. All of the abovementioned aspects may help to elucidate the molecular mechanisms underlying cisplatin resistance and may help to identify promising new therapeutic targets.

Current cancer drug targets. 2018 Jan 01 [Epub ahead of print]

Katarina Kalavska, Vincenza Conteduca, Ugo De Giorgi, Michal Mego

Faculty of Medicine, Comenius University and National Cancer Institute - Translational Research Unit Bratislava, Slovakia National Cancer Institute - Department of Oncology Bratislava, Slovakia Slovak Academy of Sciences - Cancer Research Institute Brat. Slovakia., Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS - Medical Oncology Department Meldola. Italy., Faculty of Medicine, Comenius University and National Cancer Institute - Translational Research Unit Bratislava, Slovakia National Cancer Institute - Department of Oncology Bratislava, Slovakia Faculty of Medicine, Comenius University and National Cance. Slovakia.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe